Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison
The Journal of Allergy and Clinical Immunology: In Practice · 2024-12 · 12 (12) · 3393-3401.e15
DOI: 10.1016/j.jaip.2024.09.015 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-12. Verfasst von Claire Hopkins und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Guy's Hospital, London, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sinusitis, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Dupilumab and mepolizumab have shown efficacy and safety in treating chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: Without available results from head-to-head randomized control trials (RCTs) comparing dupilumab with other biologics, we conducted an indirect treatment comparison (ITC) with mepolizumab. METHODS: A systematic literature review identified RCTs of biologics in CRSwNP. A Bucher ITC was performed, including nasal polyp score (NPS; range 0-8), nasal congestion (NC; 0-3), loss of smell (LOS; 0-3), University of Pennsylvania Smell Identification Test (UPSIT; 0-40), visual analog score (VAS; 0-10), Sino-Nasal Outcome Test (SNOT-22; 0-110), systemic corticosteroid (SCS) use or surgery for nasal polyps (NPs), and binary responder analyses for NPS and SNOT-22 improvement by ≥1/≥2 and ≥8.9, respectively. Matching-adjusted indirect comparisons (MAICs) were conducted as supporting analyses. RESULTS: SINUS-24/-52 (SYNAPSE-like subpopulation only) and SYNAPSE were identified for ITC. At 24 weeks, the change from baseline in NPS and the proportion of patients with a binary responder outcome of NPS improvement ≥1 were significantly (P < .05) greater in those receiving dupilumab than those receiving mepolizumab. At 52 weeks, improvements in NPS, NC, LOS, UPSIT, and VAS were significantly (P < .05) greater for dupilumab than mepolizumab. The proportion of patients achieving binary responder outcomes of NPS and SNOT-22 improvement by ≥1/≥2 and ≥8.9, respectively, was significantly (P < .05) higher, whereas SCS use was significantly (P < .05) reduced, for dupilumab versus mepolizumab. Surgery rate was numerically reduced with dupilumab versus mepolizumab. The MAIC analyses confirmed these results. CONCLUSION: Dupilumab was associated with greater improvements in CRSwNP-related outcomes versus mepolizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Guy's Hospital, London, United Kingdom.
- Eastern Virginia Medical School, Norfolk, Va.
- Department of Otorhinolaryngology, Amsterdam UMC, Amsterdam, the Netherlands.
- Department of Otorhinolaryngology, Heinrich Heine University Düsseldorf, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.
- Global Health Economics & Value Assessment, Sanofi, Gentilly, France.
- Global Medical, Sanofi, Chilly-Mazarin, France.
Zitieren
APA
Hopkins, C., Han, J. K., Fokkens, W., Wagenmann, M., Guyot, P., Khan, A. H., Nash, S., Wang, Z., Xu, Y., Msihid, J., Neupane, B., Nag, A., & Bachert, C. (2024). Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison. The Journal of Allergy and Clinical Immunology: In Practice, 12(12), 3393-3401.e15. https://doi.org/10.1016/j.jaip.2024.09.015
Vancouver
Hopkins C, Han JK, Fokkens W, Wagenmann M, Guyot P, Khan AH, et al. Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(12):3393-3401.e15. doi:10.1016/j.jaip.2024.09.015
BibTeX
@article{Hopkins2024,
author = {Hopkins, Claire and Han, Joseph K and Fokkens, Wytske and Wagenmann, Martin and Guyot, Patricia and Khan, Asif H and Nash, Scott and Wang, Zhixiao and Xu, Yingxin and Msihid, Jérôme and Neupane, Binod and Nag, Arpita and Bachert, Claus},
title = {Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2024},
volume = {12},
number = {12},
pages = {3393--3401.e15},
doi = {10.1016/j.jaip.2024.09.015}
}
EUVIMED